MR spectroscopy of hepatic fat and adiponectin and leptin levels during testosterone therapy in type 2 diabetes: a randomized, double-blinded, placebo-controlled trial: A randomized, double-blinded, placebo-controlled trial

L V Magnussen, P E Andersen, Alejandro Rafael Diaz, J Ostojic, K. Højlund, D. M. Hougaard, Anders Nymark Christensen, T. L. Nielsen, M Andersen

Research output: Contribution to journalJournal articleResearchpeer-review

147 Downloads (Pure)


Men with type 2 diabetes mellitus (T2D) often have lowered testosterone levels and an increased risk of cardiovascular disease (CVD). Ectopic fat increases the risk of CVD, whereas subcutaneous gluteofemoral fat protects against CVD and has a beneficial adipokine-secreting profile. Testosterone replacement therapy (TRT) may reduce the content of ectopic fat and improve the adipokine profile in men with T2D. A randomized, double-blinded, placebo-controlled study in 39 men aged 50-70 years with T2D and bioavailable testosterone levels
Original languageEnglish
JournalEuropean Journal of Endocrinology
Issue number2
Pages (from-to)157-168
Publication statusPublished - 2017

Cite this